Rowachol (Tillotts) is a mixture of monoterpenes intended for the dissolution of cholesterol gallstones, as an adjunct to the existing drugs chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) whose use we discussed last month.1 When combined with CDCA, Rowachol is claimed to dissolve stones in the common duct. This article assesses its efficacy both alone and in combination therapy.
A clinical studies on gallstone patients rate in multiphasic healthy testing system and gallstone dissolution therapy. Comparison of efficacy between the single administration of ursodeoxycholic acid (UDC) and the combined therapy of UDC and chenodeoxycholic acid (CDC).